Lilly manufacturing head bows out along with compliance chief

March 9, 2021

Eli Lilly have announced the upcoming retirement of two executive committee members and the naming of their successors in the company's manufacturing operations and ethics and compliance organizations.

Myles O'Neill, senior vice president and president of Lilly manufacturing operations, will retire May 2 after nearly 19 years of service with the company. Melissa Barnes, senior vice president and chief ethics and compliance officer, will retire June 27, after more than 26 years with the company.

"Lilly is in the midst of an exciting period of growth and is driven by our purpose to create new medicines for people in need around the world. Today we announce two planned retirements of long-tenured and successful executives and the promotion of Edgardo and Alonzo, both of whom are well prepared to assume their new roles," said David A. Ricks, Lilly chairman and CEO.

Hernandez earned his bachelor's degree in chemical engineering from the University of Puerto Rico – Mayaguez and his master's in chemical engineering from North Carolina State University. Prior to joining Lilly in 2005, Hernandez worked for Pfizer. His career at Lilly has included roles with increasing leadership responsibilities in engineering services and manufacturing strategy, as well as manufacturing site-head roles in Puerto Rico, France and the United States. He currently oversees Lilly's parenteral and device manufacturing network, as well as the company's global supply chain activities.

Alonzo Weems earned his bachelor's degree in English from Wabash College and his Doctor of Jurisprudence from Indiana University Maurer School of Law. Prior to joining Lilly in 1997, Weems was an attorney for the National Labor Relations Board. He has held roles of increasing responsibility at Lilly, including general counsel of Lilly Canada, general counsel for Lilly USA and general counsel for the global Bio-Medicines and Diabetes business units, which included responsibilities for legal teams in Australia, Canada, China, Europe and Japan. In his current role, Weems is responsible for the corporate legal functions which includes commercial transactions, litigation, regulatory and human resources.

Read the Eli Lilly statement